Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•11/08/2026•07:00 ET
0
Whiz Insights
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter
Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026
Get started
Create a free account to read the full story.